In Vivo Binding Activity of Recombinant ScFv Against HBsAg in HBV Transgenic Mice

熊盛,王一飞,邢少膊,邓宁,张美英,陈文吟,饶桂荣,粟宽源,余宙耀

DOI: https://doi.org/10.3760/j:issn:0254-5101.2004.05.009

2004-01-01

Abstract:Objective To investigate the activity of recombinant single-chain Fv against HBsAg (HBscFv) in HBV transgenic mice, and the possibility of applying HBV transgenic mice as a model to evaluate the binding-activity of HBsAg specific antibodies. Methods Produced from recombinant E.coli M15[pQE-HBscFv], inclusion body of HBscFv was purified by immobilized metal chelation and gel filtration chromatography, and then renaturated by dialysis step-by-step. HBscFv product was injected into the tail vein of HBV transgenic mice and the concentration of HBsAg in mice sera was determined by sandwich ELISA. The decreasing degree of HBsAg concentration, defined as binding rate, was calculated. At the same time, HBsAb IgG from human blood was used as positive control, with 0.9% NaCl as negative control. Results The recombinant HBscFv was able to be purified to a purity as high as 98% by two-step method. The binding rate of HBscFv was (30.47±9.85)%, that was different significantly with that of NaCl solution ( P 0.001) and not different with that of HBsAb IgG ( P 0.05). The binding rate of HBsAb IgG was (39.00±7.43)%, that was different significantly with that of NaCl solution ( P 0.001). Comparing the binding rate and protein concentration of HBscFv with those of HBsAb IgG, the binding titer of HBscFv was determined to be 31.58U/mg. Conclusion HBscFv has in vivo HBsAg-binding activity in HBV transgenic mice, which might be developed into a candidate model to evaluate the in vivo binding activity of HBsAg specific antibodies.